- Describe common opportunistic infections seen among persons with HIV
- Cite reasons for opportunistic infections in 2022
- Determine when to start antiretroviral therapy in the setting of an opportunistic infection
This module will provide an overview of opportunitistic infections for the HIV care team. Part of the conference "HIV: the Basics" session, the module will explore what members of the care team should know about opportunistic infections.
William R. Short, MD, MPH, FIDSA
Associate Professor of Medicine
Perelman School of Medicine, University of Pennsylvania
William R. Short, MD, MPH, FIDSA is an Associate Professor of Medicine with a secondary appointment in Obstetrics and Gynecology at the Perelman School of Medicine, University of Pennsylvania. Dr. Short graduated with his Doctor of Medicine degree from Hahnemann University. Subsequently he completed an internship, residency, and Chief residency in Internal Medicine followed by an Infectious Diseases Fellowship at the MCP/Hahnemann University. Locally, Dr. Short serves as the Associate Director of the Penn HIV Clinical Trials Unit (ACTU) and maintains two active clinical practices one in the Penn Community Practice and the second in the Helen O. Dickens OB/GYN Clinic, where he is involved in the care of pregnant women living with HIV. Nationally, he serves on the following: Scientific/Clinical Member of the Department of Health and Human Services (DHHS) Panel for Treatment of HIV-infected Pregnant Women and Prevention of Perinatal Transmission; Member of the HIV Primary Care Guideline Panel; Member of the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV; Advisor to the Antiretroviral Pregnancy Registry (APR); Vice-chair for the American Academy of HIV Medicine (AAHIVM) and finally as a Member of the Taskforce for the Elimination of Perinatal HIV Transmission in the United States and Co-chair of the Preconception Care for women with HIV working group.
This accredited continuing education activity is provided by American Academy of CME, Inc.
The 16th Annual American Conference for the Treatment of HIV (ACTHIV 2021) was held May 5-7, 2022. The conference and this Best of ACTHIV web archive were supported by educational grants from Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; Merck, Theratechnologies, and ViiV Healthcare.
William R. Short, MD, MPH, Associate Professor of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Estimated time to complete: 30 minutes
This activity is intended for frontline providers of care to persons at risk for or who are living with HIV, including specialist and primary care Physicians, NPs, PAs, Nurses, and Pharmacists. Other HIV care team members are also encouraged to participate.
American Academy of CME is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Academy of CME, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses Practitioners and Nurses:
American Academy of CME, Inc. designates this educational activity for 0.5 contact hours (0.20 pharmacotherapeutic contact hours).
American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until September 15, 2023. PAs should only claim credit commensurate with the extent of their participation.
All other members of the HIV Care team will receive a certificate of participation.
HOW TO RECEIVE CREDIT
There is no fee to participate in this activity. To obtain your certificate of credit/participation, you must read the CME/CE information, review the activity content, and complete the activity assessment and evaluation. Upon submission, your CE certificate will be emailed to you within 24 hours.
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy, or ACTHIV. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Off-Label Usage Disclosure
There will be no off-label/investigational uses discussed in this presentation.
William R Short, MD, MPH, FIDSA discloses the following relevant relationships with ineligible companies: Advisory Board/Consultant – Gilead Sciences, ViiV Healthcare; Speaker’s Bureau – ViiV Healthcare, Janssen
The following individuals have no relevant financial relationships with ineligible companies to disclose: Beatrice Aladin, MD, MPA; Jillian Baron, MD, MPH; John T Brooks, MD; Jose Castillo-Mancilla, MD; Lisa Catalli, MSN, NP-C; Jonathan Colasanti, MD, MSPH; Sherrillyn Crooks, PA-C; Christopher Evans, MD; Courtney V Fletcher, PharmD; Donna Futterman, MD; Rajesh Gandhi, MD; Mary Glenshaw, PhD, MPH, OTR/L; Jose Gutierrez, PhD, MSN, FNP-BC; Tomasz Jodlowski, PharmD; John JD Juchniewicz, MCIS, CHCP, FACEHP; Natalie Kirkwood, RN, BSN, JD; Jennifer Kay-Berene Klein, MSN; Harry Lampiris, MD; Sharon Lee, MD; Vincent Lo Re, MD, MSCE; Amber McCracken; Lorenzo McFarland, DHA, MPH, MSW, PMP; Paul Miniter, MS; Edward Moylan, RP; Asa Radix, MD, PhD, MPH; Dianne Rausch, PhD; Aaron Richterman, MD MPH; Jeri (Jieri) Sumitani, MMSc, PA-C; Pablo Tebas, MD; Ronald Dean Wilcox MD; Darcy Wooten, MD, MS
The following individuals have relevant financial relationships with ineligible companies to disclose:
Dawn Averitt, BIS: Advisory Board/Consultant – Merck, Gilead Sciences, ViiV Healthcare
Roger Bedimo, MD, MS: Advisory Board/Consultant – Merck, ViiV Healthcare, Theratechnologies*
Eric Daar, MD: Advisory Board/Consultant – Merck, Gilead Sciences, ViiV Healthcare; Grant/Research Support – Gilead Sciences, ViiV Healthcare
Carlos del Rio, MD: Advisory Board/Consultant: Resverolix, Sanofi-Pasteur*
Margaret Hoffman-Terry, MD, FACP, AAHIVS: Advisory Board/Consultant – ViiV Healthcare; Grant/Research Support – ViiV Healthcare; Speakers Bureau – Gilead Sciences, ViiV Healthcare
H. Nina Kim, MD, MSc: Grant/Research Support – Gilead Sciences
Igho Ofotokun, MD, MSc: Grant/Research Support – Merck
Tonia Poteat, PhD, MPH, PA-C: Advisory Board/Consultant – Merck, ViiV Healthcare
Jennifer Price, MD, PhD: Advisory Board/Consultant – Theratechnologies, Gilead Sciences, Merck; Grant/Research Support – Gilead Sciences, Merck; Speaker’s Bureau – Gilead Sciences
Jason Schafer, PharmD, MPH: Advisory Board/Consultant – Merck, ViiV Healthcare; Grant/Research Support – Merck, Gilead Sciences*
Renslow Sherer MD: Grant/Research Support – Gilead Sciences
William R Short, MD, MPH, FIDSA: Advisory Board/Consultant – Gilead Sciences, ViiV Healthcare; Speaker’s Bureau – ViiV Healthcare, Janssen
Babaafemi Taiwo, MBBS: Advisory Board/Consultant – Gilead Sciences, Merck, ViiV Healthcare, Janssen
Melanie Thompson, MD: Grant/Research Support – Cepheid Inc, Cytodyn Inc, Frontier Biotechnologies, Gilead Sciences, GlaxoSmithKline, Merck, ViiV Healthcare
Andrea Weddle, MSW: Policy Consultation: Merck
Susan Weiss, FNP-BC, MSN, AAHIVS: Advisory Board* – Gilead Sciences, Merck, ViiV Healthcare, Janssen; Speaker’s Bureau* – Gilead Sciences, ViiV Healthcare, Janssen
*Indicates relationship has ended
For questions related to CME/CE credit, contact CEservices@academycme.org
Hardware/Software Requirements To access this activity hardware and software requirements are noted below.
Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later
Copyright 2022 American Academy of CME, Inc.
- Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new